Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng

Clin Mol Hepatol. 2025;31(2):620-624. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1131

View: 1133 Download: 47 Crossref: 2

Original Article

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):525-547. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0835

View: 2704 Download: 256 Crossref: 5

Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma

Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):453-464. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0450

View: 4830 Download: 135 Web of Science: 4 Crossref: 5

Editorial

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 4009 Download: 94 Web of Science: 2 Crossref: 1

Original Article

Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States

Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang

Received February 12, 2025 Accepted April 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0169 [Accepted]

View: 420 Download: 35

1 |

Viewed By 8477	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7415	MAFLD: How is it different from NAFLD?
Viewed By 5377	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5007	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4547	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 319	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 291	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search